2018
A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers
Roberts W, Verplaetse TL, Moore KE, Oberleitner LM, McKee SA. A preliminary investigation into the effects of doxazosin on cognitive functioning in tobacco‐deprived and ‐satiated smokers. Human Psychopharmacology Clinical And Experimental 2018, 33: e2660. PMID: 29878501, PMCID: PMC5995328, DOI: 10.1002/hup.2660.Peer-Reviewed Original ResearchConceptsContinuous performance taskInhibitory controlCognitive functioningPerformance taskTobacco withdrawalEffects of doxazosinSustained attentionCognitive performanceWithdrawal symptomsCognitive AssessmentSmoking outcomesMost measuresSelf-reported withdrawal symptomsReaction timeTaskParticipantsFunctioningPredrug levelsΑ1 antagonistTitration periodGreater improvementDoxazosinSmokingSymptomsPreliminary investigation
2015
Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, Mazure CM, McKee SA. Targeting the Noradrenergic System for Gender-Sensitive Medication Development for Tobacco Dependence. Nicotine & Tobacco Research 2015, 17: 486-495. PMID: 25762760, PMCID: PMC4432402, DOI: 10.1093/ntr/ntu280.Peer-Reviewed Original ResearchMeSH KeywordsFemaleGender IdentityHumansMaleNicotineReceptors, AndrogenSmoking CessationSmoking PreventionSubstance Withdrawal SyndromeConceptsSmoking cessationNoradrenergic systemClinical evidenceTobacco dependenceNoradrenergic activityMedication developmentPoor smoking cessation outcomesCause of morbiditySmoking cessation outcomesStress reactivitySex-specific mechanismsLower quit ratesNicotine-related reinforcementCurrent medicationsMedication effectivenessNicotine reinforcementCessation outcomesNoradrenergic agentsQuit ratesTreatment strategiesTobacco useNoradrenergic compoundsSmoking outcomesTreatment developmentWomen